Sabril Benefits In Infantile Spasms Outweigh Risk Of Vision Loss, Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Ovation anti-epileptic gains second unanimous approval recommendation from FDA committee; limited clinical data on vision loss means post-market studies are likely.
You may also be interested in...
The REMS Double Down: Two Indications, Two REMS For Ovation’s Sabril?
If FDA follows an advisory committee's advice to approve Ovation's Sabril (vigabatrin) for two separate epilepsy indications, it may require a first for the REMS era: two Risk Evaluation and Mitigation Strategies for a single product
The REMS Double Down: Two Indications, Two REMS For Ovation’s Sabril?
If FDA follows an advisory committee's advice to approve Ovation's Sabril (vigabatrin) for two separate epilepsy indications, it may require a first for the REMS era: two Risk Evaluation and Mitigation Strategies for a single product
Ovation’s Sabril Gets Advisory Committee Nod; Risk Strategy To Address Vision Loss Needed
The recommendation is contingent upon development of a REMS to detect the risk of visual field defects.